Vital

Progress and nutrition

GLP-1 Weight Loss Tracker: Trial Results by Week and a Chart

How to use a GLP-1 weight loss tracker well: what the tirzepatide and semaglutide trials reported at each week, how to work out percent body weight lost, how to measure your waist, and a chart template.

Last reviewed

The Vital angle

With Apple Health access on, Vital reads your weight and charts it with waist size, body fat, lean body mass, steps and sleep, and you choose which charts to show. You can log a waist measurement in Vital and it saves to Apple Health. The same trends screen shows your dose cadence and a calendar of logged doses.

GLP-1 weight loss tracker: what to record

A GLP-1 weight loss tracker works best when it records three things together: your weight on a fixed routine, your waist measurement, and your dose history. Weight alone moves up and down with water, salt and the time of day. Percent of starting weight, a monthly waist number and the dose you were on at each point give you and your prescriber a clearer picture than any single weigh-in.

For context, the large trials measured progress over many months, not weeks. In the SURMOUNT-1 trial of tirzepatide, mean weight change at week 72 was -15.0%, -19.5% and -20.9% on the 5, 10 and 15 mg arms, against -3.1% on placebo. In the STEP 1 trial of semaglutide 2.4 mg, it was -14.9% at week 68, against -2.4% on placebo. These are averages for large groups. Your own curve can be faster, slower or flat for weeks and still fall inside what the trials saw.

What the trials showed by week

The table lists published results at the weeks where the trials reported them. All results are means for the trial group, not targets.

Week Trial and drug What was reported
0 to 20 SURMOUNT-1, tirzepatide Dose escalation period. Arms reached their assigned dose during these 20 weeks
36 SURMOUNT-4, tirzepatide, open-label at the maximum tolerated dose (10 or 15 mg) Mean -20.9% for the 670 people who completed the lead-in
68 STEP 1, semaglutide 2.4 mg Mean -14.9%, against -2.4% on placebo. 86.4% lost 5% or more
72 SURMOUNT-1, tirzepatide 5, 10 and 15 mg Mean -15.0%, -19.5% and -20.9%, against -3.1% on placebo
88 SURMOUNT-4, tirzepatide continued Mean -25.3% from week 0 for people who stayed on the drug
88 SURMOUNT-4, switched to placebo at week 36 Mean regain of 14.0% from week 36. Overall change from week 0 was -9.9%

Two lessons come out of these numbers. First, the 72-week results include the 20-week escalation, so early weeks on a low starting dose are not a fair test of the full effect. Second, SURMOUNT-4 showed that stopping tirzepatide led to substantial regain, so a tracker is useful over the long term, not only at the start.

Tirzepatide weight loss week by week: what to expect from your own chart

The Zepbound label lists a starting dose of 2.5 mg once weekly for 4 weeks, then 5 mg, with increases in 2.5 mg steps after at least 4 weeks on the current dose. The label lists 5, 10 or 15 mg once weekly as maintenance doses. Your prescriber sets your own steps.

What this means for a week-by-week chart:

  • Daily weight moves. A change of 1 to 2 pounds from one day to the next is often water, not fat. Compare weekly averages, not single days.
  • Mark each dose step. A note on the chart at each step lets you compare the weeks before and after it.
  • Plateaus happen. A flat stretch of a few weeks is common. See weight loss plateaus before you change anything.
  • Trial curves are averages. The average hides people who lost more and people who lost less.

For the drug level side of the picture, see the free GLP-1 level chart and GLP-1 medication level chart.

How to work out percent body weight lost

Trials report percent change because it compares people of different sizes. Use the same number in your tracker.

  1. Write down your starting weight, taken on your first dose day.
  2. Subtract your current weight from the starting weight.
  3. Divide the result by the starting weight.
  4. Multiply by 100.

Math example: a start of 220 lb and a current weight of 198 lb is a 22 lb loss. 22 ÷ 220 = 0.10, so the loss is 10% of starting body weight. The free weight loss calculator does this for you in pounds or kilograms.

The NHLBI says health professionals recommend losing 5% to 10% of starting weight over about 6 months for people with overweight or obesity. Ask your prescriber which goal fits you.

How to take a waist measurement

Waist size tracks belly fat, and it can keep falling during a weight plateau. The SURMOUNT-1 results on the Zepbound label show mean waist changes at week 72 of -14.0 cm, -17.7 cm and -18.5 cm on the three tirzepatide arms, against -4.0 cm on placebo.

The NHLBI method is simple:

  1. Stand, and place a tape measure around your middle, just above your hip bones.
  2. Breathe out, then read the tape.

For a fair comparison over time, keep the tape level all the way around and measure at the same time of day, such as in the morning before you eat.

The NHLBI says a waist of more than 35 inches for women or more than 40 inches for men increases the risk of heart disease and type 2 diabetes. Once a week or once a month is enough for this number.

Weight loss chart template

Copy this template into a notebook or a spreadsheet. One row per week is enough.

Week Date Dose (as prescribed) Weekly average weight Change from start (%) Waist Notes (sleep, side effects, dose step)
0 0% Start
1
2
4
  • Weigh on the same scale, at the same time, in similar clothes.
  • Work out the weekly average from your daily weigh-ins, if you weigh daily.
  • Note each dose change in the same row as the weight, so cause and effect stay together.

How Vital tracks your progress

Vital shows your health trends next to your dose history. With Apple Health access turned on, it reads your weight and charts it over time, along with measures such as waist size, body fat, lean body mass, steps and sleep. You can choose which charts to show and hide the rest. You can log a waist measurement in Vital, and it saves to Apple Health. The same screen shows your dose cadence and a calendar of the days you logged a dose, so you can see how a dose step lines up with your weight trend.

Vital is a tracking tool, not a medical device. It does not set goals or change doses. If your data does not appear, see Apple Health sync not working. For a wider comparison of apps, see the best GLP-1 tracker app, and for Zepbound-specific tips, see Zepbound vial units.

When to call your prescriber

A tracker can show a trend that needs a clinician. Call your prescriber if:

  • You lose weight much faster than expected, or you cannot eat enough to keep up your strength. See protein on GLP-1.
  • You have no change at all after several months on a maintenance dose. See tirzepatide not working.
  • You feel dizzy, faint or very tired.

Get emergency care for severe stomach pain that does not go away, with or without vomiting, vomiting that stops you from keeping fluids down, or swelling of the face or throat.


Zepbound® is a trademark of Eli Lilly and Company. Vital is independent and not affiliated with these companies.

Free toolWeight loss percentage calculator

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • Single-day weigh-ins

    Day-to-day weight moves with water, salt and time of day. A weekly average from a fixed routine shows the trend more clearly.

  • Judging results during dose escalation

    SURMOUNT-1 included a 20-week dose escalation period, so early weeks on a starting dose do not show the full effect seen at week 72.

  • Trial averages used as personal targets

    Trial results such as -20.9% at week 72 are group means. Individual results were spread above and below them.

  • Stopping treatment without a plan

    In SURMOUNT-4, people switched to placebo at week 36 regained a mean 14.0% by week 88. Talk to the prescriber before stopping.

  • Inconsistent waist measurements

    Waist size changes with where and when you measure. The NHLBI method is just above the hip bones, read after you breathe out.

Frequently asked questions

  • Trials report results at set weeks, not every week. In SURMOUNT-1, mean change at week 72 was -15.0% to -20.9% by dose, against -3.1% on placebo. In SURMOUNT-4, the mean was -20.9% after a 36-week open-label lead-in.

  • Subtract your current weight from your starting weight, divide by the starting weight, and multiply by 100. A drop from 220 lb to 198 lb is 10%.

  • Stand, place a tape measure around your middle just above your hip bones, breathe out, then read it. Measure at the same time of day each time, weekly or monthly.

  • Day-to-day weight moves with water, salt and time of day. Compare weekly averages. If you see no change after several months on a maintenance dose, talk to your prescriber.

  • Weight on a fixed routine, waist size, the dose and date of each injection, dose changes, and side effects. Keeping dose and weight together shows how a dose step lines up with the trend.

  • In SURMOUNT-4, people switched to placebo after 36 weeks regained a mean 14.0% by week 88, while people who continued lost more. Ask your prescriber before you stop.

Sources

  1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · New England Journal of Medicine, via PubMed
  2. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4) · JAMA, via PubMed
  3. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) · New England Journal of Medicine, via PubMed
  4. Zepbound (tirzepatide) injection prescribing information · DailyMed, U.S. National Library of Medicine
  5. Heart-Healthy Living: Aim for a Healthy Weight · National Heart, Lung, and Blood Institute

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.